Journal Article

An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders

La Piana, Roberta, Casas, Diana, Alluli, Aeshah, Thomas, Rhalena A., Aprahamian, Nathalia, MacDonald, Adam, MacDougall, Emma J., Antel, Jack P., Dudley, Roy W. R., Durcan, Thomas M., Karpilovsky, Nathan, Schneider, Alexandria, Dorion, Marie-France, Shlaifer, Irina, Chen, Carol X.-Q., Fleming, Peter, Goldsmith, Taylor M., Yaqubi, Moein, Nicouleau, Michael, Piscopo, Valerio E. C., Hall, Jeffrey A., Healy, Luke M., Fon, Edward A., Dorion, Samuel, Stratton, Jo Anne

2024

Overview

Background Induced pluripotent stem cell-derived microglia (iMGL) represent an excellent tool in studying microglial function in health and disease. Yet, since differentiation and survival of iMGL are highly reliant on colony-stimulating factor 1 receptor (CSF1R) signaling, it is difficult to use iMGL to study microglial dysfunction associated with pathogenic defects in CSF1R. Methods Serial modifications to an existing iMGL protocol were made, including but not limited to changes in growth factor combination to drive microglial differentiation, until successful derivation of microglia-like cells from an adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) patient carrying a c.2350G > A (p.V784M) CSF1R variant. Using healthy control lines, the quality of the new iMGL protocol was validated through cell yield assessment, measurement of microglia marker expression, transcriptomic comparison to primary microglia, and evaluation of inflammatory and phagocytic activities. Similarly, molecular and functional characterization of the ALSP patient-derived iMGL was carried out in comparison to healthy control iMGL. Results The newly devised protocol allowed the generation of iMGL with enhanced transcriptomic similarity to cultured primary human microglia and with higher scavenging and inflammatory competence at ~ threefold greater yield compared to the original protocol. Using this protocol, decreased CSF1R autophosphorylation and cell surface expression was observed in iMGL derived from the ALSP patient compared to those derived from healthy controls. Additionally, ALSP patient-derived iMGL presented a migratory defect accompanying a temporal reduction in purinergic receptor P2Y12 ( P2RY12 ) expression, a heightened capacity to internalize myelin, as well as heightened inflammatory response to Pam 3 CSK 4 . Poor P2RY12 expression was confirmed to be a consequence of CSF1R haploinsufficiency, as this feature was also observed following CSF1R knockdown or inhibition in mature control iMGL, and in CSF1R WT/KO and CSF1R WT/E633K iMGL compared to their respective isogenic controls. Conclusions We optimized a pre-existing iMGL protocol, generating a powerful tool to study microglial involvement in human neurological diseases. Using the optimized protocol, we have generated for the first time iMGL from an ALSP patient carrying a pathogenic CSF1R variant, with preliminary characterization pointing toward functional alterations in migratory, phagocytic and inflammatory activities. Graphical Abstract

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: ALSP / Biomedical and Life Sciences / Biomedicine / Cell surface / Colony-stimulating factor / Consent / Cryopreservation / CSF1R / Ethylenediaminetetraacetic acid / Haploinsufficiency / Inflammation / iPSC / Kinases / Leukoencephalopathy / Macrophage colony-stimulating factor / Medical research / Medicine, Experimental / Microglia / Molecular Medicine / Myelin / Nervous system diseases / Neurological diseases / Neurology / Neurosciences / Phagocytes / Phagocytosis / Pluripotency / Research Article / Scientific equipment and supplies industry / Spheroids / Stem cells / Transcriptomics